Puumala virus (PUUV, carried by Myodes glareolus) co-circulates with Seewis virus (SWSV, carried by Sorex araneus) in Finland. While PUUV causes 1000-3000 nephropathia epidemica (NE) cases annually, the pathogenicity of SWSV to man is unknown. To study the prevalence of SWSV antibodies in hantavirus fever-like patients' sera, we used recombinant SWSV nucleocapsid (N) protein as the antigen in ELISA, immunofluorescence assay (IFA) and immunoblotting. While characterizing the recombinant SWSV N protein, we observed that a polyclonal rabbit antiserum against PUUV N protein cross-reacted with SWSV N protein and vice versa. We initially screened 486 (450 PUUV-seronegative and 36 PUUV-seropositive) samples sent to Helsinki University Hospital Laboratory for PUUV serodiagnosis during 2002 and 2007 in an SWSV N protein IgG ELISA. In total, 4.2 % (19/450) of the PUUVseronegative samples were reactive in the SWSV N protein IgG ELISA and none of the tested samples [43 PUUV-seronegative (weakly reactive in the SWSV IgG ELISA) and 15 random] were reactive in the SWSV N protein IgM ELISA. None of the IgG reactions could be confirmed by IFA or immunoblotting. Furthermore, among the 36 PUUV-seropositive samples three were reactive in SWSV N protein IgG and ten in SWSV N protein IgM ELISA. One PUUVseropositive sample reacted with SWSV N protein in IFA and four in immunoblotting. Finally, we applied competitive ELISA to confirm that the observed reactivity was due to cross-reactivity rather than a true SWSV response. In conclusion, no evidence of SWSV infection was found among the 486 samples studied; however, we did demonstrate that PUUV antiserum cross-reacted with shrew-borne hantavirus N protein.
INTRODUCTION
Hantaviruses (genus Hantavirus, family Bunyaviridae) are enzootic to small mammals including rodents, soricomorphs (shrews and moles) and bats (Guo et al., 2013) . If transmitted to man the rodent-borne hantaviruses may cause either haemorrhagic fever with renal syndrome (HFRS) or hantavirus cardiopulmonary syndrome (HCPS) (Jonsson et al., 2010) . HFRS is primarily caused by Old World hantaviruses: Hantaan virus (HTNV), Seoul virus (SEOV), Puumala virus (PUUV) and Dobrava-Belgrade virus. The causative agents of HCPS are the New World hantaviruses such as Sin Nombre virus and Andes virus. In humans, hantavirus pathogenesis is triggered by the direct effects of the virus on endothelial cells and monocyte-macrophages and by activation of the innate and adaptive immune system Vaheri et al., 2013) . Typical symptoms of hantavirus infection include fever, nausea, dizziness, blurred vision, joint and muscle pain and impairment of renal functions, but it may also be accompanied by secondary infections (Macé et al., 2013; Vaheri et al., 2013) . Hantavirus fever has been suggested as a common denominator for the human disease (Clement et al., 2014) . Currently, it is not known whether the hantaviruses found in shrews, moles or bats can infect humans.
The negative-sense RNA genome of hantaviruses comprises three segments, S, M and L that respectively encode nucleocapsid (N) protein, glycoprotein precursor and RNAdependent RNA polymerase (Hepojoki et al., 2012; Jonsson et al., 2010; Vaheri et al., 2013) . N protein is the immunodominant viral protein and is conventionally used as the antigen in serodiagnosis (Vaheri et al., 2008; Yoshimatsu & Arikawa, 2014a) . In addition to group-and genuscommon epitopes, N protein also harbours serotypespecific epitopes Tischler et al., 2008) . The cross-reactivity of N protein between rodentborne hantaviruses is common and such epitopes usually locate to the coiled-coil structure in the N terminus of the N protein (Saasa et al., 2012) . This essential structural motif is also found in the N protein of the prototype shrew-borne hantavirus, Thottapalayam virus (TMPV, carried by Suncus murinus). TMPV, found in Asia, is distant from rodent-borne hantaviruses in phylogeny and the N protein of TMPV has been reported not to react with antiserum against rodent-borne hantaviruses (Schlegel et al., 2012a; Song et al., 2007a) .
Seewis virus (SWSV) RNA was initially identified from archival common shrew (Sorex araneus) samples in Switzerland (Song et al., 2007b) . To our knowledge cell culture isolates of SWSV do not exist, which to some extent compromises the use of the term virus; however, for the sake of clarity we will use SWSV when referring to Seewis virus. Soon after its discovery, SWSV was also detected in Austria, the Czech Republic, Finland, Germany, Hungary, Poland, Russia, Slovakia and Slovenia (Kang et al., 2009; Ling et al., 2014; Resman et al., 2013; Schlegel et al., 2012b; Song et al., 2007b; Yashina et al., 2010) . SWSV is divided into three genotypes; the Finnish subtype is distant from both the Russian and Central European SWSV subtypes. SWSV shares its most recent common ancestor with the Muridae-associated hantaviruses HTNV and SEOV, which is considered to be due to a horizontal transmission event between the rodents and soricomorphs (Plyusnin & Sironen, 2014) . The prevalence of SWSV is fairly high and about 12 to 14 % of common shrews are positive for SWSV RNA (Ling et al., 2014; Schlegel et al., 2012b) . SWSV is geographically widespread but the evidence for SWSV existence is limited to nucleic acid detection and serological evidence is lacking. To date, neither RNA nor antigenic evidence of SWSV infection in humans has been presented. To study whether SWSV could be transmitted to and cause a disease similar to hantavirus fever in man, we performed a serological survey using a panel of 486 serum samples collected from febrile illness patients. We would expect this set of samples to be a sentinel target for other hantavirus infections, should they occur in Finland. The responses of the antiserum towards recombinant SWSV N protein were evaluated in various assays.
RESULTS
We decided to use recombinant SWSV N protein expressed in insect cells to study the serological responses since our attempts at SWSV isolation had been unsuccessful. Furthermore, it has been shown that serological response against hantavirus N protein can be used in serodiagnosis (Vapalahti et al., 1995b) . A histidine-tagged recombinant SWSV N protein was produced in High Five cells (Fig.  1a) through baculovirus expression vector systems. Samples taken at different steps of the purification were analysed by SDS-PAGE (Fig. 1b) . The purified protein ( Fig. 1b ; lane 5) was confirmed by immunoblotting to react with both the SWSV antiserum and heart extracts of SWSV RNA-positive shrew samples (containing specific anti-SWSV N protein IgG, approximately 160 kDa) (Fig.  1d) . Both the size and immunoreactivity of the recombinant protein confirmed it was the SWSV N protein.
Immunofluorescence assay (IFA), based on staining of infected Vero E6 cells with patient serum, has been in routine use for serodiagnosis of hantavirus infection for decades (Vapalahti et al., 1995a) . We therefore wanted to test whether SWSV N protein produced via recombinant expression in Vero E6 cells could be used to analyse the serological response against SWSV. The diagnostic slides for IFA were prepared from Vero E6 cells transfected with pcDNA3.1(+)-SWSVN, pcDNA3-TULVN and pcDNA3-PUUVN and fixed in acetone. Indeed, we detected SWSV N protein expressed in Vero E6 cells using shrew heart extracts as the source of antibody (Fig. 1c) , indicating the functionality of our IFA system for antibody determination. Staining with both rabbit anti-SWSV and rabbit anti-PUUV N protein antisera indicated cross-reactivity (Fig. 2) . Irrespective of the serum used, a typical N protein immunostaining pattern with granular fluorescence pattern in the cytoplasm was evident (Kaukinen et al., 2003; Li et al., 2002) . Stronger fluorescence staining is expected with a homologous antigen-antibody pairs compared with heterologous pairs; indeed SWSV antiserum showed a titre of 31 250 for SWSV N protein while that against PUUV N protein was only 50. Similarly, PUUV antisera had a titre of 31 250 against PUUV N protein but also exhibited a high titre (6 250) against the SWSV N protein. This result indicates, quite unexpectedly, that SWSV N protein antiserum cross-reacts with the N proteins of Arvicolinae-borne PUUV (and also TULV, results not shown). Since the antiserum against SWSV N protein was raised against a recombinant protein containing the first 120 aa (Fig. 1f) , this result further indicates that the N-terminal region is highly cross-reactive, as discussed earlier (Yoshimatsu & Arikawa, 2014a) .
To further study the observed cross-reactivity and to characterize the antigenicity of SWSV N protein, we decided to use immunoblotting and IFA. The recombinant SWSV and PUUV N proteins were studied separately in SDS-PAGE, transferred onto nitrocellulose membrane and immunoblotted with a panel of hantavirus N-specific mAbs 4C3, 2E12, 3C11, 3 F10, 2D9, 1F1, 2H6, 2E7, ECO2, E5G6 and F23A1 (descriptions and references in Table 1 ). The reactivity of the same antibodies was also studied by IFA. PUUV N protein was recognized by mAbs 4C3, 2E12 and E5G6 as previously reported (Lundkvist et al., 1991; Schlegel et al., 2012a; Yoshimatsu et al., 1996) , but none of the mAbs reacted with SWSV N protein. However, the polyclonal rabbit antiserum against the first 120 aa of SWSV N protein reacted with PUUV N protein in immunoblotting, further demonstrating the antigenic similarity of this region (Fig. 3a) . Moreover, the predicted 3D structures of the SWSV and PUUV N proteins' N terminus are homologous, both containing three helices that assemble as an antiparallel coiled-coil structure (Fig. 1e) . Alignment of the first 120 aa of PUUV, TULV, HTNV, TMPV and SWSV N proteins highlighted a shared common linear epitope ( Fig. 1f) , further suggesting that epitope mimicry accounts for the observed cross-reactivity.
To study whether the cross-reactivity would cause problems in ELISA-based serodiagnosis, we coated recombinant SWSV and recombinant PUUV N protein onto ELISA plates. We initially used these plates to test the cross-reactivity of rabbit anti-PUUV and rabbit anti-SWSV N protein antisera by titration. Both antisera produced absorbance values higher than the pre-immunization serum (negative control) for both antigens (Fig. 3b) . The titre of anti-PUUV N protein antiserum was approximately 10 2 -10 3 higher than that of anti-SWSV N protein antiserum. The observed difference in titre could be explained by the different size of the antigen used (SWSV N antisera were produced against 1-120 aa and PUUV N antisera against 1-267 aa). Based on results from ELISA we found both antibodies recognized both antigens, although the reactivity of SWSV N protein antiserum was modest, which was in line with IFA intensities and titration results.
Once we had established and characterized the recombinant SWSV N protein ELISA for its cross-reactivity, we decided to use this test to study whether SWSV could be The mAbs for PUUV, 4C3 and 2E12 are described in Lundkvist et al. (1991) ; TULV, 3C11 and 3F10 are described in Vapalahti et al. (1995b) ; TMPV, 2D9, 1F1, 2H6 and 2E7 are described in Schlegel et al. (2012a) ; HTNV, ECO2, E5G6 and F23A1 are described in Yoshimatsu et al. (1996) . The polyclonal antibodies for PUUV and SWSV have been described previously (Ling et al., 2014; Vapalahti et al., 1995b) . transmitted to man (i.e. to look for SWSV antibodies in human serum). With this in mind, we screened a panel of PUUV-seronegative and PUUV-seropositive serum samples for the presence of SWSV antibodies using ELISA with recombinant SWSV N protein as the antigen. We used a panel of sera collected from healthy donors (Finnish maternity serum panel, n598) to determine the cut-off limits for both SWSV and PUUV N protein IgG and IgM ELISA. The absorbance cut-off values for SWSV N protein IgG/IgM ELISA were low A50.75/0.27 and high A50.88/0.31 and for PUUV N protein IgG/IgM ELISA low A50.68/0.29 and high A50.88/0.32 (Fig. 4b) . Among 450 PUUVseronegative samples 43 (9.6 %) gave an absorbance value above the lower IgG cut-off and 19 (4.2 %) above the higher cut-off limit in SWSV N protein IgG ELISA. To further test the seroreactivity of the 43 positive samples and other randomly chosen 15 samples (in total 58 samples), we measured IgM antibodies using SWSV N protein ELISA, however absorbance values below the higher cut-off were detected with all samples (Fig. 4a) .
We further compared and analysed the IgG and IgM reactivity of PUUV-seropositive patient sera against SWSV and PUUV N protein ELISA.
The absorbance values of all tested samples were above the lower PUUV N protein IgG ELISA cut-off and 26 out of 36 samples were also positive in PUUV N protein IgM ELISA. These results were in agreement with the diagnostic results of the HUSLAB (Helsinki University Hospital) reference test (IFA on Vero E6 cells infected with PUUV and m-capture PUUV IgM ELISA). In total we found 3 and 10 out of 36 samples to be reactive in both SWSV and PUUV N protein IgG/IgM ELISA, respectively. Moreover, the antibody reactivity had no obvious correlation between SWSV and PUUV N ELISA, with R 2 50.0194 for IgG and R 2 50.2496 for IgM (Fig. 3c) , indicating that the degree of cross-reactivity was rather low.
To confirm that the reaction towards SWSV N protein IgG ELISA was caused by a cross-reaction, we analysed the positive samples with both IFA and immunoblot. None of the 43 samples showed reactivity towards recombinant SWSV N protein in IFA or in immunoblot. This suggests that the observed signal in the ELISA was due to a crossreaction or some form of an unspecific reaction rather than an actual anti-SWSV antibody response. We also analysed a panel of 36 PUUV-seropositive serum samples in IFA with pcDNA3.1(+)-PUUN and pcDNA3.1(+)-SWSN transfected Vero E6 cells. While all samples were positive in PUUV IFA, a single patient (no. 28) showed a modest reactivity towards SWSV N protein in IFA. To further assess the reactivity of PUUV-seropositive sera towards SWSV N protein, we analysed the samples by immunoblotting. Four samples (including no. 28) yielded a positive result with both PUUV and SWSV N protein (respective bands at around 50 and 48 kDa, with the corresponding absorbance values below, Fig. 4c) . Three of the studied samples (nos 45, 73 and 77) were SWSV N protein seronegative in the IFA and ELISA, but showed modest reactivity with SWSV N in immunoblotting (Fig. 4c) .
To further assess the IgG cross-reactivity of human sera between SWSV and PUUV N protein, we performed an antigen and antiserum competition ELISA with three seroreactive samples (nos 28, 37 and 75). A decline close to the lower cut-off was observed when the competition was done with PUUV N protein or PUUV antiserum, whereas no significant effect was observed when pre-treated with SWSV N protein antiserum. The seroreactivity in the SWSV N protein ELISA was not altered when using antigen or antiserum as the competing agent. Only sample no. 28 showed modest changes in SWSV N protein ELISA reactivity with the SWSV or PUUV antiserum as the competing agents (Fig. 4d) . This suggests, together with the IFA results, that the reactivity of these samples in SWSV N protein ELISA is likely a cross-reaction.
DISCUSSION
In this study, we used a panel of serum samples collected from febrile illness patients in Finland to look for acute SWSV infections and putative seroprevalence of SWSV. The selected samples were sent to HUSLAB for PUUV serodiagnosis, but diagnosed as PUUV-seronegative. The sample panel was studied by ELISA, IFA and immunoblotting for IgG/IgM antibodies towards SWSV and PUUV N protein.
Our results demonstrate that SWSV is not likely to infect man despite SWSV infection occurring frequently in shrews (prevalence 12-14 %), which are abundant in Finland. However, our results demonstrate a serological crossreactivity between SWSV and PUUV N protein, two hantaviruses that co-circulate in Finland.
The gold standard for serotyping of hantavirus infection is the plaque reduction neutralization test (PRNT). However, PRNT requires special technical skills and a biosafety level-3 laboratory and thus it is not widely applied. Also, to set up a PRNT test one would need either to have a virus isolate or express the glycoproteins in virus-like particles with a reporter system. Unfortunately, neither of these currently exists for SWSV, thus hampering the development of specific serological tests for SWSV. The N protein is the immunodominant structural protein of hantaviruses. The N-terminal region of the hantavirus N protein harbours common epitopes responsible for the cross-reactivity between different hantaviruses, and some serotyping assays have been developed by deleting this region from the recombinant N protein (Yoshimatsu & Arikawa, 2014b) . SWSV and PUUV are genetically distant from one another and share only 58.6-61.1 % identity at the nucleotide level and 55.9-59.6 % identity at the amino acid level.
We observed that the first 120 aa of SWSV and PUUV shared, in addition to conformational features, some linear epitopes. Furthermore we found that SWSV N protein antiserum raised against the first 120 aa of the SWSV N protein reacted with PUUV N protein in both IFA and immunoblotting experiments. When analysing serum samples of patients suspected of hantavirus infection for SWSV N antibodies, we found no SWSV-specific responses. However, a few of the studied PUUV-seropositive samples were reactive for recombinant SWSV N protein in ELISA, IFA and immunoblotting experiments, indicating a potential cross-reactivity as discussed previously (Goeijenbier et al., 2014) . Four of the PUUV-seropositive sera were tested for the presence of linear epitopes for SWSV N protein in immunoblotting experiments. One of the four, no. 28, cross-reacted weakly with the SWSV N protein, probably due to epitope mimicry; however, the cross-reactivity was very weak. We ruled out specific recognition of the SWSV N protein by performing a PUUV IFA test in parallel. Therefore, we believe it would be highly unlikely for cross-reactivity to result in a misdiagnosis between SWSV and PUUV infections.
Taken together, our data suggests that SWSV does not infect humans. However, human SWSV infections cannot be completely ruled out, since the carrier of SWSV, Sorex areneus, is only rarely in contact with people. Thus the putative human SWSV infection might be too infrequent to be detected by our approach. Future studies should include samples collected from people with higher chance of exposure, like woodcutters or biologists doing fieldwork.
Serology has been the main approach to finding new viruses associated with disease in the pre-gene-technology era.
The initial identification of PUUV in Finland was done using a lung tissue section from a bank vole that was used as antigen for sera of nephropathia epidemica patients. Interestingly, early work with HTNV antigen also observed a cross-reaction phenomenon (Lähdevirta et al., 1984; Lee & Cho, 1981) . The prototype of shrew-borne hantaviruses, TPMV, was isolated incidentally during a survey for Japanese encephalitis virus in southern India in 1946 (Carey et al., 1971) . For a long time, this was mistakenly regarded as an exception to rodent-borne hantaviruses until its genome was fully sequenced (Song et al., 2007a) . From 2007 onwards, increasing numbers of novel hantaviruses have been discovered from soricomorphs and bats using pan-L (partial polymerase L gene) reverse transcriptase (RT)-PCR. Furthermore, these mammals are actually now suspected as carriers of hantaviruses according to previous serological surveys of rodent-borne hantaviruses. This illustrates that the cross-reaction phenomenon between novel hantaviruses has been neglected to some extent, although serological cross-reactions in similarly distant hantaviruses have been discussed previously (Chu et al., 1994) . For instance, TPMV (whole-virus particles) cross-reacted slightly with SEOV-like sera in ELISA, with HTNV and SEOV-like sera in HI (hemagglutination inhibition) and none in PRNT (Chu et al., 1994) . S. araneus has been established as a host of SWSV; the hantavirus antigen was found in its tissues using ELISA as early as 1982 (Gavrilovskaya et al., 1983) . In Finland, bank voles and common shrews, which are commonly found together in the same habitats, have been screened for hantavirus antibodies using IFA (Voutilainen et al., 2012) , but no obvious positive reactions were found from S. araneus samples, most probably due to the fact that the anti-mouse secondary antibodies cross-reacted with the shrew IgG at a low level (Schlegel et al., 2012b) . It is quite likely that more soricomorph-borne hantaviruses will be discovered in the near future. Currently, no clear consensus exists on the relationship between shrew-and rodent-borne hantaviruses. A more thorough cross-reactivity study may help to understand hantavirus evolution, and may even help discover more shrew-borne hantaviruses to be added to the hantavirus phylogeny (Bennett et al., 2014) .
In conclusion, we could not demonstrate SWSV antibodies in the studied sample panel. This suggests that it is quite unlikely or rarely that SWSV infects or induces disease in humans. Our results suggest that the SWSV N protein cross-reactive antibodies may be found in PUUV-seropositive individuals. This region responsible for the observed crossreactivity is most likely located in the first 120 aa of the N protein, which harbours a common folding motif and some conserved amino acid regions. However, we conclude that such cross-reactivity would not interfere with PUUV serodiagnosis when utilizing commonly applied techniques. Serological studies using glycoproteins as antigen might shed further light on the potential SWSV transmission to humans; however, the recombinant expression of hantavirus glycoproteins is somewhat challenging.
METHODS
Ethics statement. This study was performed in accordance with the research permit granted to HUSLAB, Department of Virology and Immunology. All patient samples were handled anonymously. Cells, plasmids and antibodies. Mammalian (Vero E6) and insect (SF6 cells and High Five cells) cells were cultured in Dulbecco's modified Eagle's medium (Gibco) and Sf-900 II SFM (Life Technologies), respectively. Both media were supplemented with 10 % heatinactivated FCS, 2 mM L-glutamine, 100 IU penicillin ml 21 and 100 mg streptomycin ml
21
. The mammalian cells were maintained at 37 uC in a humidified atmosphere containing 5 % CO 2 and the insect cells at 27 uC without supplementary CO 2 . mAbs against PUUV N protein: 4C3 and 2E12 (both react towards the N terminus) (Lundkvist et al., 1991) ; TULV N protein: 3C11 (N terminus) and 3F10 (226-294 aa) Vapalahti et al., 1999) ; HTNV N protein: ECO2 (N terminus), E5G6 (165-173 aa); and F23A1 (291-402 aa) described by Yoshimatsu et al. (1996) were obtained from ProfessorÅ ke Lundkvist (University of Uppsala) and Professor Jiro Arikawa (Hokkaido University) and were stored at 220 uC prior to use. TMPV N protein-specific mAbs 2D9, 1F1, 2H6 and 2E7 (N terminus) were obtained from Professor Rainer G. Ulrich (Friedrich-Loeffler Institut).
The production of polyclonal rabbit antisera against the N-terminal (1-120 aa) fragment of SWSV N protein and the N-terminal fragment (1-267 aa) of the PUUV N protein were described previously (Ling et al., 2014; Vapalahti et al., 1995b) . The mammalian expression plasmids for TULV and PUUV N, pcDNA3.1(+)-TULVN and pcDNA3.1(+)-PUUVN, were constructed elsewhere (Kaukinen et al., 2003; Li et al., 2002) . The coding region of the SWSV N protein (Finnish strain; GenBank accession no. KJ136609) was amplified by RT-PCR. Total RNA was extracted from frozen shrew lung tissues using TriSure reagent (Bioline), and cDNA was transcribed using a RevertAid H minus First Strand cDNA Synthesis kit (Thermo scientific) in a 20 ml reaction containing 1 ml random hexamers (20 pmol random hexamers ml 21 ), 1 ml universal primer 59-TAGTAGTAGA-CTCC-39, 1 ml dNTP (10 mM) and 5 ml RNA. PCR was performed using Phusion Flash (Thermo scientific). Restriction sites Nhe I and HindIII (underlined) were introduced by primers (fwd 59-CTAGCTAGCCACCATGGAGGATACAAAACAGTTTGA-39 and rev 59-CCCAAGCTTCAGCTTCATTGGCTCCATATTAG-39) for cloning into pcDNA3.1(+) (Invitrogen). The amplified product after Nhe I and HindIII (Thermo Scientific) treatment was ligated with a vector cut with the same enzymes, yielding the expression construct pcDNA3.1(+)-SWSN. The insert was verified by DNA sequencing. Shrew heart extracts from an earlier study (Ling et al., 2014) were used to characterize the recombinant SWSV N protein produced in insect cells. Recombinant antigens, SWSV and PUUV N protein. Purified recombinant PUUV N protein described by Vapalahti et al. (1995b) was obtained from Reagena. The Bac-to-Bac TOPO Expression System (Invitrogen) was used for the expression of SWSV N protein. Briefly, Fwd59-ATGGAGGATACAAAACAGTTTGA-39 and Rev59-CAGCTTCATTGGCTCCATATTAG-39 primers were used to generate a blunt-end PCR product of the SWSV N protein (Finnish strain, GenBank accession number KJ136609) coding sequence without a stop codon. The blunt-end PCR product was used to generate a bacmid according to the instructions in the Bac-to-Bac TOPO Expression System (Invitrogen) and the presence of SWSV N coding sequence was verified by sequencing. The bacmid was transfected to Sf6 cells and the recombinant baculovirus collected at 3 to 5 days posttransfection was used to infect High Five cells for protein expression. His6-tagged SWSV N protein was purified by immobilized metal-ion affinity chromatography (IMAC) as described by (Hepojoki et al., 2015) . The concentration of the recombinant proteins was determined using the BCA Protein Assay kit (Thermo Scientific).
Alignment and structure predication of PUUV and SWSV N proteins. The sequences of PUUV and SWSV N proteins were aligned using CLUSTAL W and BioEdit (version 7.0.9.0; www.mbio.ncsu.edu/BioEdit/bioedit.html) and the three-dimensional structure prediction was done using the Rosetta program (http://robetta. bakerlab.org).
Immunoblotting assays. For standard immunoblots, the recombinant hantavirus N proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes by wet blotting. The membranes were probed with either human sera samples (1: 100) or polyclonal rabbit antisera against SWSV and PUUV N protein (in 10-fold dilution series) using the basic protocol described by Hetzel et al. (2013) , with IRDye 800CW Donkey anti-Human IgG (H+L) (1: 15 000) and IRDye 800CW Donkey anti-Rabbit IgG (H+L) (1: 15 000) as the secondary antibodies.
When analysing shrew samples for antibodies, 2 ml of heart extract from both SWS-RNA-positive and -negative shrews were separated by SDS-PAGE under non-reducing conditions and wet blotted onto nitrocellulose. The membrane was first probed with 1 mg recombinant SWSV N ml 21 (1: 500), washed, probed with polyclonal anti-SWSV N antisera (1: 5000), washed and finally probed with IRDye 800CW Donkey anti-Rabbit IgG (H+L) (1: 15 000). All immunoblots were recorded using an Odyssey infrared imaging system (LI-COR Biosciences).
IFA. Vero E6 cells grown on coverslips in 24-well plates were transfected with the following plasmids: pcDNA3.1(+)-SWSVN, pcDNA3.1(+)-TULVN and pcDNA3.1(+)-PUUVN according to FuGENE HD Protocol (Promega) . Cells were fixed 36 h post-transfection with icecold acetone for 7 min at room temperature. The production of recombinant proteins from transfected plasmids was confirmed by immunofluorescence staining with PUUV and SWSV N proteinspecific antisera [antisera with a 5-fold dilution series (1: 50 to 1: 156 250), mAbs (1: 1000) and shrew heart extracts (1: 5)]. The presence of antigen was visualized using FITC-conjugated donkey anti-rabbit (1: 30) or -mouse IgG (1: 30) (Dako) as secondary antibodies. Nuclei were visualized using 1 mg Hoechst 33342 ml 21 (PBS). Immunofluorescence microscopy was done using a Zeiss Axioplan microscope.
Direct ELISA. For coating of 96-well microtitre plates (Polysorp; Nunc), the recombinant SWSV and PUUV N proteins were diluted with 150 ng recombinant protein ml 21 into 50 mM carbonate-bicarbonate buffer (pH 9.6), 100 ml protein dilution was dispensed per well and the plates were incubated at 37 uC for 1 h. After washing [washing buffer: PBS (pH 7.2) and 0.05 % Tween 20], the wells were blocked with 150 ml of blocking buffer (PBS containing 5 % BSA; Sigma) for 1 h at 37 uC. After five washes, serum samples (1: 100 in PBS) were dispensed (100 ml per well) followed by 1 h incubation at room temperature. After five washes, HRP-conjugated anti-human IgG or IgM (Dako, 1: 5000 in PBS, 100 ml per well) was added and the plates incubated at room temperature for 1 h, followed by five washes. The plate with tetramethylbenzidine (Thermo Scientific) substrate (100 ml per well) was incubated for 15 min at room temperature, the reaction was stopped by the addition of 1 M H 2 SO 4 (50 ml per well) and the results (absorbance at 450 nm) were read using a Multiscan plate reader (Labsystems).
To determine the titre of PUUV N1-267 and SWSVN1-120 antisera, those with a 10-fold dilution series (1: 10 2 to 1: 10 7 ) were used in combination with swine anti-rabbit IgG (Dako, 1: 1000 dilution in PBS) as secondary antibody.
All samples in ELISA were analysed in duplicate. Cut-off values (lower cut-off, mean+3|SD; higher cut-off, mean+4|SD) were set for SWSV and PUUV N IgM and IgG ELISA set using the absorbance values obtained from the negative control samples (Finnish maternity sera cohort, n598). The samples with mean absorbance values exceeding the higher cut-off were considered PUUV-or SWSV IgGpositive. Samples having absorbance values between the cut-off levels were classified as inconclusive. The samples with absorbance values above the low SWSV N protein IgG or IgM ELISA cut-off were confirmed by IFA and immunoblotting. Competitive ELISA (see below) was used to evaluate samples IgG positive for both SWSV and PUUV.
Competitive ELISA. Serum samples positive in both SWSV and PUUV N protein IgG ELISA were further studied by competitive ELISA for the degree of antigenic cross-reactivity. Two different types of competitive ELISA were applied: competition with antigen and competition with polyclonal antibodies. The assay was performed in a similar manner as described above, but by either pre-adsorbing the serum with a series of diluted antigens (SWSVN1-120, SWSVN1-429 and PUUVN1-433) or by pre-incubation with (serially diluted) rabbit anti-SWSV or anti-PUUV antisera for 2 h at room temperature (Fig. 4d) .
